Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GODAVARI DRUGS LTD. · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GODAVARI DRUGS LTD.
BSE: 530317
BSE: 530317
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
GODAVARI DRUGS LTD.
StateQ4 FY26 filed
Last close · 9 Oct 2026₹130.40
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA24.4 · 1.77 · 17.1
GODAVARI DRUGS LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 161 | 160 | 157 | 113 | 106 |
| EBITDA (ex other income) | 11 | 10 | 13 | 12 | 11 |
| margin % | 7.0 | 6.4 | 8.4 | 10.4 | 10.1 |
| Owners' profit | 5 | 4 | 6 | 4 | 4 |
| EPS, as reported (₹) | 6.97 | 5.03 | 7.37 | 5.82 | 5.43 |
| ROE % · ROCE % | 17.7 · 22.6 | 11.3 · 18.6 | 14.2 · 22.4 | 10.1 · 14.8 | 5.4 · 7.8 |
| Debt / equity (x) | 0.69 | 1.00 | 1.43 | 1.42 | 1.01 |
| Cash from operations | 11 | 13 | 18 | 11 | 1 |
| Capex | (5) | (9) | (13) | (20) | (27) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GODAVARI DRUGS LTD. · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32 | 26 | 30 | 26 | 24 | 27 | 22 | 33 |
| Profit before tax | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Net profit | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS (₹) | 2.17 | 1.45 | 1.02 | 1.19 | 1.38 | 1.33 | 1.01 | 1.71 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,22,229 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,48,067 | 84.9 | 14.80 | 64.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,270 | 73.8 | 8.89 | 38.8 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,10,978 | 24.8 | 3.75 | 14.4 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,07,937 | 98.6 | 19.87 | 60.1 | 16.4 | 17.2 | 7.2 | 32.0 |
| CIPLA LTD | 1,05,570 | 31.3 | 3.06 | 16.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| DR. REDDY S LABORATORIES | 98,530 | 30.5 | 2.58 | 13.2 | 10.9 | 13.0 | 12.1 | 15.0 |
| MANKIND PHARMA LIMITED | 98,294 | 48.1 | 5.94 | 27.1 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 23.8 | 31.2 | 56 of 158 | 65% |
| P/B | 1.7 | 3.1 | 44 of 163 | 74% |
| ROCE | 4.4 | 10.8 | 130 of 183 | 29% |
| ROE | 5.4 | 9.8 | 114 of 166 | 32% |
| Debt / Equity | 1.0 | 0.2 | 154 of 166 | 7% |
| EBITDA margin | 9.6 | 17.5 | 122 of 165 | 26% |
| Revenue growth | 30.0 | 16.3 | 47 of 161 | 71% |
| Profit growth | 44.5 | 30.9 | 70 of 158 | 56% |
| Market cap | 131 | 857 | 126 of 181 | 31% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GODAVARI DRUGS LTD. · 9 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 26 Sept 2026 · Godavari Drugs 38th AGM: all 4 resolutions passed, plans entry into nutraceuticals | board shareholder meetings | low | — | — |
| 25 Sept 2026 · Godavari Drugs 38th AGM: DHDT trials done, nutraceuticals push approved | board shareholder meetings | low | — | — |
| 21 Sept 2026 · Trading window closure from October 1 for half-yearly results | compliance | minimal | — | — |
| 3 Sept 2026 · Physical AGM notice dispatched to shareholders without registered email | compliance | minimal | — | — |
| 3 Sept 2026 · Godavari Drugs 38th AGM notice: 25 Sep 2026 via video conference | compliance | minimal | — | — |
| 1 Sept 2026 · 38th AGM notice - September 25, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 1 Sept 2026 · 38th AGM Notice on Sep 25, 2026; Special Resolution to Add Nutraceuticals | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Godavari Drugs fixes book closure for 38th AGM on 25 Sep 2026 | corporate actions | low | — | — |
| 1 Sept 2026 · Godavari Drugs to add nutraceuticals and food ingredients business via MOA amendment | strategic transactions | medium | — | — |
| 31 Aug 2026 · Board approves entry into nutraceuticals and food ingredients business | corporate actions | medium | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in